EyeArt® News

Eyenuk’s AI Eye Screening System for Diabetic Retinopathy Demonstrates Exceptional Performance in a Prospective, Multi-Center, Pivotal Clinical Trial

LOS ANGELES, Calif., April 28, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark prospective, multi-center, pivotal clinical trial to validate the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR),

Researchers Study Improvement in Patient Compliance and Screening Efficacy by Using the EyeArt AI Eye Screening System for Detecting Diabetic Retinopathy

LOS ANGELES, June 5, 2019 – Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that data from scientific studies related to the screening efficacy of the EyeArt® AI Eye Screening System and the impact of using the EyeArt AI

Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February

– 30 Centers Across Italy Will Provide AI Eye Screening for Diabetic Retinopathy, the Leading Cause of Vision Loss Among Working-age Adults – LOS ANGELES–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it is providing EyeArt® AI Eye

Eyenuk, Inc. presents EyeArt™ 2.0 at EASDec 2016 in Manchester

Eyenuk, Inc. will be attending the twenty-sixth EASDec 2016 conference in Manchester, UK from June 23rd to June 25th. Along with hosting a booth, Eyenuk CEO, Kaushal Solanki, will be presenting Eyenuk’s EyeArt™ 2.0 technology during Session 5 of the conference: “Imaging and New Technologies” on Saturday June 25 at 9:00am GMT. EASDec is a study group of the